Ulviprubart

Ulviprubart (ABC-008) is a monoclonal antibody targeting the KLRG1 receptor that selectively depletes highly differentiated cytotoxic T cells. Ulviprubart can be used in the study of inclusion body myositis (IBM) [1].

Product Specifications

CAS Number

[2569434-60-0]

Product Name Alternative

ABC-008

UNSPSC

12352203

Target

C-type Lectin-like Receptors (CTLRs)

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ulviprubart.html

Purity

99.68

Solubility

10 mM in DMSO

Smiles

[Ulviprubart]

Molecular Weight

(146.96 kDa)

References & Citations

[1]Brady S, et al. Inclusion body myositis: Correcting mitochondfrial and lysosomal autophagy impairment as a potential therapeutic strategy[J]. Autoimmunity Reviews, 2024: 103644.|[2]Konry T, et al., Single Cell Droplet-Based Efficacy and Transcriptomic Analysis of a Novel Anti-KLRG1 Antibody for Elimination of Autoreactive T Cells. Res Sq [Preprint]. 2024 Sep 8:rs.3.rs-4745216.